ClinicalTrials.gg
TerminatedNCT05752123Updated Mar 30, 2025

A Study to Evaluate the Safety and Efficacy of ET-01 Transplantation in Subjects with Transfusion Dependent Β-Thalassaemia.

An interventional study of ET-01 in Transfusion Dependent Beta-Thalassaemia, sponsored by EdiGene (GuangZhou) Inc.. Terminated at 1 site in China. Open to participants aged 6 Years to 35 Years. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by EdiGene (GuangZhou) Inc. · Not applicable, Interventional, and Treatment

Why this study was terminated
Development plan change

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
6 Years to 35 Years
Sex
All
01

Study summary

This is an open label, single site study to evaluate the safety and Efficacy of ET-01 Transplantation in subjects with Transfusion Dependent β-Thalassaemia.

02

Conditions studied

  • Transfusion Dependent Beta-Thalassaemia
03

In context

Lead sponsor

EdiGene (GuangZhou) Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Subject and/or subject's legal personal representative fully understand and voluntarily sign forms;
  • 6\~35 years old, all gender;
  • Diagnosis of transfusion dependent β-thalassemia (β-TDT) as defined by protocol;
  • Eligible for stem cell transplant;
  • Organs in good function.

Other protocol defined Inclusion criteria may apply.

Key Exclusion Criteria:

  • Subjects with associated α-thalassemia;
  • Active bacterial, virus, fungal or parasitic infection, including infection, HbsAg and positive, DNA positive, or Treponema Pallidum infection;
  • HLA identical sibling or unrelated donors are available;
  • Prior allo-HSCT or gene therapy.

Other protocol defined Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    ET-01

    BCL11A Enhancer modified Autologous Hematopoietic Stem Cells

    Biological: ET-01

Interventions

  • BiologicalET-01

    Recruited participants will receive ET-01 IV infusion after conditioning.

06

What researchers measure

Primary outcomes

  1. Frequency and severity of AEs & SAEs identified according to NCI CTCAE 5.0.

    Time frame: From ET-01 infusion to 104 weeks post-transplant

  2. All-cause mortality.

    Time frame: From signing of informed consent to 104 weeks post-transplant

  3. Incidence of transplant-related mortality.

    Time frame: within 100 days post-transplant

  4. Proportion of subjects with engraftment.

    Time frame: up to 42 days post-transplant

Secondary outcomes

  1. Change in total hemoglobin from baseline.

    Time frame: within 104 weeks post-transplant

  2. Change of HbF from baseline.

    Time frame: within 104 weeks post-transplant

  3. Change of proportion of HbF/Hb.

    Time frame: within 104 weeks post-transplant

  4. Change of frequency of packed RBC transfusions.

    Time frame: From 6 months before recruitment to 104 weeks post-transplant

  5. Change of volume of packed RBC transfusions.

    Time frame: From 6 months before recruitment to 104 weeks post-transplant

07

Study locations

1 site
  • PLA 923 Hospital
    Nanning, Guangxi 530021, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Jan 2024, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2023
First posted
Mar 2, 2023
StartActual
Feb 18, 2023
Primary completionActual
Jan 29, 2024
CompletionActual
Mar 12, 2025
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05752123
Lead sponsor
EdiGene (GuangZhou) Inc.
Collaborators
The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army
Responsible party
Sponsor
First posted
Mar 2, 2023
Start date
Feb 18, 2023
Primary completion
Jan 29, 2024
Completion
Mar 12, 2025
Last update
Mar 30, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ET-01

Start the discussion